The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

PubChem12777     quinolin-4-amine

Synonyms: CHEMBL58146, SureCN278276, SureCN291391, CCRIS 1679, AG-C-04090, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of quinolin-4-amine

 

High impact information on quinolin-4-amine

 

Chemical compound and disease context of quinolin-4-amine

 

Biological context of quinolin-4-amine

 

Anatomical context of quinolin-4-amine

 

Associations of quinolin-4-amine with other chemical compounds

 

Gene context of quinolin-4-amine

 

Analytical, diagnostic and therapeutic context of quinolin-4-amine

  • However, it was concluded that BoTx m.e.p.p.s do not originate from the Schwann cells because denervation of BoTx-paralysed frogs abolishes all m.e.p.p.s and the drug 4-aminoquinoline affects BoTx m.e.p.p.s and Schwann m.e.p.p.s in opposite ways, increasing the frequency of the former while almost eliminating the latter [31].
  • The electrophysiological effects of 4-aminoquinoline (4-AQ), a drug structurally related to 4-aminopyridine, were studied on the sinus venosus of the frog Caudiverbera caudiverbera with standard microelectrode techniques [16].

References

  1. Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Diaz-Arrastia, C., Arany, I., Robazetti, S.C., Dinh, T.V., Gatalica, Z., Tyring, S.K., Hannigan, E. Clin. Cancer Res. (2001) [Pubmed]
  2. Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. O'Neill, P.M., Mukhtar, A., Stocks, P.A., Randle, L.E., Hindley, S., Ward, S.A., Storr, R.C., Bickley, J.F., O'Neil, I.A., Maggs, J.L., Hughes, R.H., Winstanley, P.A., Bray, P.G., Park, B.K. J. Med. Chem. (2003) [Pubmed]
  3. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. Warhurst, D.C., Steele, J.C., Adagu, I.S., Craig, J.C., Cullander, C. J. Antimicrob. Chemother. (2003) [Pubmed]
  4. Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. Naisbitt, D.J., Ruscoe, J.E., Williams, D., O'Neill, P.M., Pirmohamed, M., Park, B.K. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  5. Chloroquine-induced pruritus among patients with malaria. Osifo, N.G. Archives of dermatology. (1984) [Pubmed]
  6. Dichlorquinazine (alpha 4-aminoquinoline) effective in vitro against chloroquine-resistant Plasmodium falciparum. Le Bras, J., Deloron, P., Charmot, G. Lancet (1983) [Pubmed]
  7. Antimalarial drugs and pregnancy. Parke, A. Am. J. Med. (1988) [Pubmed]
  8. Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. Alifrangis, M., Dalgaard, M.B., Lusingu, J.P., Vestergaard, L.S., Staalsoe, T., Jensen, A.T., Enevold, A., Rønn, A.M., Khalil, I.F., Warhurst, D.C., Lemnge, M.M., Theander, T.G., Bygbjerg, I.C. J. Infect. Dis. (2006) [Pubmed]
  9. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Basco, L.K., Ringwald, P. Antimicrob. Agents Chemother. (2003) [Pubmed]
  10. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. Dvir, H., Wong, D.M., Harel, M., Barril, X., Orozco, M., Luque, F.J., Muñoz-Torrero, D., Camps, P., Rosenberry, T.L., Silman, I., Sussman, J.L. Biochemistry (2002) [Pubmed]
  11. Combined mutagenicity of cobalt(II) salt and heteroaromatic compounds in Salmonella typhimurium. Ogawa, H.I., Sakata, K., Inouye, T., Jyosui, S., Niyitani, Y., Kakimoto, K., Morishita, M., Tsuruta, S., Kato, Y. Mutat. Res. (1986) [Pubmed]
  12. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Gilman, A.L., Chan, K.W., Mogul, A., Morris, C., Goldman, F.D., Boyer, M., Cirenza, E., Mazumder, A., Gehan, E., Cahill, R., Frankel, S., Schultz, K. Biol. Blood Marrow Transplant. (2000) [Pubmed]
  13. Structure-activity relationships in 4-aminoquinoline antiplasmodials. The role of the group at the 7-position. Kaschula, C.H., Egan, T.J., Hunter, R., Basilico, N., Parapini, S., Taramelli, D., Pasini, E., Monti, D. J. Med. Chem. (2002) [Pubmed]
  14. Organ-specific DNA damage induced in mice by the organotropic carcinogens 4-nitroquinoline 1-oxide and dimethylnitrosamine. Laishes, B.A., Koropatnick, D.J., Stich, H.F. Proc. Soc. Exp. Biol. Med. (1975) [Pubmed]
  15. 4-Aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation. Nguyen, T.Q., Capra, J.D., Sontheimer, R.D. Lupus (1998) [Pubmed]
  16. Effects of 4-aminoquinoline on action potentials of the frog sinus venosus. Guerrero, S. Archives internationales de pharmacodynamie et de thérapie. (1982) [Pubmed]
  17. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Cutler, D.J., MacIntyre, A.C., Tett, S.E. Agents Actions Suppl. (1988) [Pubmed]
  18. The nature and origin of calcium-insensitive miniature end-plate potentials at rodent neuromuscular junctions. Lupa, M.T., Tabti, N., Thesleff, S., Vyskocil, F., Yu, S.P. J. Physiol. (Lond.) (1986) [Pubmed]
  19. Differential effects of 4-aminoquinoline-containing antimalarial drugs on hemoglobin digestion in Plasmodium falciparum-infected erythrocytes. Famin, O., Ginsburg, H. Biochem. Pharmacol. (2002) [Pubmed]
  20. A new type of transmitter release at the neuromuscular junction. Thesleff, S., Molgó, J. Neuroscience (1983) [Pubmed]
  21. Double-drug development against antioxidant enzymes from Plasmodium falciparum. Biot, C., Dessolin, J., Grellier, P., Davioud-Charvet, E. Redox Rep. (2003) [Pubmed]
  22. Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. Sweeney, G.D. Clin. Biochem. (1986) [Pubmed]
  23. Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues. O'Neill, P.M., Willock, D.J., Hawley, S.R., Bray, P.G., Storr, R.C., Ward, S.A., Park, B.K. J. Med. Chem. (1997) [Pubmed]
  24. The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea. Boelaert, J.R., Sperber, K., Piette, J. Biochem. Pharmacol. (2001) [Pubmed]
  25. Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. Casey, G.J., Ginny, M., Uranoli, M., Mueller, I., Reeder, J.C., Genton, B., Cowman, A.F. Am. J. Trop. Med. Hyg. (2004) [Pubmed]
  26. Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. Chiyanzu, I., Clarkson, C., Smith, P.J., Lehman, J., Gut, J., Rosenthal, P.J., Chibale, K. Bioorg. Med. Chem. (2005) [Pubmed]
  27. Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline-based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities. Han, Y.F., Li, C.P., Chow, E., Wang, H., Pang, Y.P., Carlier, P.R. Bioorg. Med. Chem. (1999) [Pubmed]
  28. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. Davioud-Charvet, E., Delarue, S., Biot, C., Schwöbel, B., Boehme, C.C., Müssigbrodt, A., Maes, L., Sergheraert, C., Grellier, P., Schirmer, R.H., Becker, K. J. Med. Chem. (2001) [Pubmed]
  29. Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Borden, M.B., Parke, A.L. Drug safety : an international journal of medical toxicology and drug experience. (2001) [Pubmed]
  30. 4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Pinard, E., Alanine, A., Bourson, A., Büttelmann, B., Heitz, M., Mutela Ramanjit Gill, V., Trube, G., Wyler, R. Bioorg. Med. Chem. Lett. (2002) [Pubmed]
  31. A comparison of miniature end-plate potentials at normal, denervated, and long-term botulinum toxin type A poisoned frog neuromuscular junctions. Lupa, M.T., Yu, S.P. Pflugers Arch. (1986) [Pubmed]
 
WikiGenes - Universities